Needham analyst Rajvindra Gill maintains Cerence (NASDAQ:CRNC) with a Buy and raises the price target from $30 to $40.
Karyopharm Therapeutics Q3 EPS $(0.45) Beats $(0.57) Estimate, Sales $36.15M Beat $34.56M Estimate
Karyopharm Therapeutics (NASDAQ:KPTI) reported quarterly losses of $(0.45) per share which beat the analyst consensus estimate of $(0.57) by 21.05 percent. This is a 34.78 percent increase over losses of $(0.69) per
